Incannex Healthcare Appoints Three New Members to Clinical Advisory Board for PSX-001 Program

Incannex Healthcare Inc.

Appointed Murray B. Stein, MD, MPH (UCSD); Andrew Cutler, MD (SUNY Upstate); and Amir Kalali, MD to Clinical Advisory Board.
Drs. Stein, Cutler, and Kalali bring expertise in psychiatry, neurobiology, psychopharmacology, and clinical development.
CAB will advise on PSX-001 clinical trial design, endpoint selection, regulatory engagement, and development strategy.
CMO Dr. Lou Barbato stated the appointments support disciplined execution and risk management for PSX-001 program.
Incannex Healthcare (IXHL) is a Nasdaq-listed clinical-stage biopharma developing innovative combination therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.